title: Efficacy and Safety of Tenofovir and Lamivudine in Combination with Efavirenz in Patients Co-infected with Human Immunodeficiency Virus and Hepatitis B Virus in China.
abstract: BACKGROUND
  The prevalence of hepatitis B virus (HBV) infection is high among individuals infected with human immunodeficiency virus (HIV) in China. Both HIV and HBV can be treated with tenofovir disoproxil fumarate (TDF) and lamivudine (3TC), so we evaluated the safety and efficacy of combination antiretroviral therapy (ART) that included TDF, 3TC, and efavirenz (EFV) among ART-naive individuals who were co-infected with HIV and HBV.
  
  
  METHODS
  One hundred HIV/HBV co-infected ARV-naive individuals were started on the regimen of TDF, 3TC, and EFV, and the levels of plasma HBV DNA, HIV RNA, and biochemical evaluation related to the function of liver and kidney were analyzed.
  
  
  RESULTS
  Concerning efficacy, this study found that by week 48, the vast majority co-infected participants receiving this ART regimen had undetectable HBV DNA levels (71%) and/or HIV RNA levels (90%). Concerning safety, this study found that the median estimated glomerular filtration rate of participants decreased from baseline (109 ml·min-1·1.73 m-2) to week 12 (104 ml·min-1·1.73 m-2) but was almost back to baseline at week 48 (111 ml·min-1·1.73 m-2).
  
  
  CONCLUSIONS
  This combination ART regimen is safe and effective for patients with HIV/HBV co-infection.
  
  
  BACKGROUND
  ClinicalTrials.gov, NCT01751555; https://clinicaltrials.gov/ct2/show/NCT01751555.
authors.forename: Ya-Song
authors.initials: YS
authors.lastname: Wu
authors.forename: Wei-Wei
authors.initials: WW
authors.lastname: Zhang
authors.forename: Xue-Mei
authors.initials: XM
authors.lastname: Ling
authors.forename: Lian
authors.initials: L
authors.lastname: Yang
authors.forename: Shao-Biao
authors.initials: SB
authors.lastname: Huang
authors.forename: Xi-Cheng
authors.initials: XC
authors.lastname: Wang
authors.forename: Hao
authors.initials: H
authors.lastname: Wu
authors.forename: Wei-Ping
authors.initials: WP
authors.lastname: Cai
authors.forename: Min
authors.initials: M
authors.lastname: Wang
authors.forename: Hui
authors.initials: H
authors.lastname: Wang
authors.forename: Yan-Fen
authors.initials: YF
authors.lastname: Liu
authors.forename: Hao-Lan
authors.initials: HL
authors.lastname: He
authors.forename: Fei-Li
authors.initials: FL
authors.lastname: Wei
authors.forename: Zun-You
authors.initials: ZY
authors.lastname: Wu
authors.affiliation: National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100050; Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
authors.forename: Fu-Jie
authors.initials: FJ
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000378:metabolism; D000480:Alkynes; D019380:Anti-HIV Agents / Q000627:therapeutic use; D001219:Aspartate Aminotransferases / Q000378:metabolism; D048588:Benzoxazines / Q000627:therapeutic use*; D015496:CD4-Positive T-Lymphocytes / Q000378:metabolism; D060085:Coinfection / Q000188:drug therapy; D003521:Cyclopropanes; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006515:Hepatitis B virus / Q000187:drug effects / Q000472:pathogenicity; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008297:Male; D000068698:Tenofovir / Q000627:therapeutic use*
chemical_list: D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D019259:Lamivudine; D000068698:Tenofovir; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; C098320:efavirenz
references.citation: Ann Intern Med. 1999 Mar 16;130(6):461-70
references.pmid: 10075613
references.citation: Hepatobiliary Pancreat Dis Int. 2011 Apr;10(2):122-7
references.pmid: 21459717
references.citation: AIDS. 2005 Mar 24;19(6):593-601
references.pmid: 15802978
references.citation: Hepatology. 2006 Feb;43(2 Suppl 1):S221-9
references.pmid: 16447263
references.citation: Antiviral Res. 2010 Jan;85(1):303-15
references.pmid: 19887087
references.citation: Hepatology. 2010 Feb;51(2):431-4
references.pmid: 19902482
references.citation: Lancet. 2011 Apr 2;377(9772):1198-209
references.pmid: 21459211
references.citation: Saudi J Kidney Dis Transpl. 2011 Jul;22(4):769-73
references.pmid: 21743226
references.citation: J Int Assoc Physicians AIDS Care (Chic). 2011 Sep-Oct;10(5):297-302
references.pmid: 21606380
references.citation: J Hepatol. 2012 Jul;57(1):167-85
references.pmid: 22436845
references.citation: AIDS. 2012 Sep 10;26(14):1755-63
references.pmid: 22614885
references.citation: BMC Infect Dis. 2013;13:301
references.pmid: 23815472
references.citation: BMC Infect Dis. 2013;13:181
references.pmid: 23597411
references.citation: PLoS One. 2013;8(7):e68152
references.pmid: 23874527
references.citation: S Afr Med J. 2013 May;103(5):330-3
references.pmid: 23971125
references.citation: Arch Virol. 2013 Sep;158(9):1889-94
references.pmid: 23553454
references.citation: Lancet Infect Dis. 2014 Nov;14(11):1065-72
references.pmid: 25303841
references.citation: Hepatology. 1999 Nov;30(5):1302-6
references.pmid: 10534354
references.citation: Am J Kidney Dis. 2000 May;35(5):884-8
references.pmid: 10793023
references.citation: Lancet. 2002 Dec 14;360(9349):1921-6
references.pmid: 12493258
references.citation: J Infect Dis. 2004 Apr 1;189(7):1185-92
references.pmid: 15031786
references.citation: Nephron. 1990;54(1):101
references.pmid: 2136938
references.citation: J Acquir Immune Defic Syndr. 2010 Jun;54(2):191-6
references.pmid: 20032784
references.citation: Antivir Ther. 2010;15(7):963-74
references.pmid: 21041911
references.citation: Kidney Int. 2005 Apr;67(4):1381-90
references.pmid: 15780090